Rigel's RA candidate R788 fails Phase IIb trial
This article was originally published in Scrip
Executive Summary
Rigel Pharmaceuticals' novel oral rheumatoid arthritis candidate R788 (fostamatinib disodium) has failed to meet the primary endpoint of a Phase IIb trial, TASKi3.